In vivo applications of PEG liposomes: Unexpected observations

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 18, Issue 6, 2001, Pages 551-566

  Laverman, Peter ^a   Boerman, Otto C ^a   Oyen, Wim J G ^a   Corstens, Frans H M ^a   Storm, Gert ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cancer chemotherapy; Complement; Diagnostic imaging; Liposome pharmacokinetics; Mononuclear phagocyte system; Polyethyleneglycol; Scintigraphy

Indexed keywords

COMPLEMENT; DOXORUBICIN; DRUG CARRIER; LIPOSOME; MACROGOL;

CANCER; CANCER CHEMOTHERAPY; COMPLEMENT SYSTEM; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG DELIVERY SYSTEM; FLUSHING; HALF LIFE TIME; HUMAN; MONONUCLEAR PHAGOCYTE; MUCOSA INFLAMMATION; NONHUMAN; PLASMA CLEARANCE; REVIEW; SCINTIGRAPHY; SKIN TOXICITY; STOMATITIS; THORAX PAIN;

EID: 0035664157     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v18.i6.40     Document Type: Review

References (70)

1. Imaging experimental osteomyelitis using radiolabeled liposomes
2. Blood-pool imaging using technetium-99m-labeled liposomes
3. Delivery of contrast agents for positron emission tomography imaging by liposomes
4. Liposome-encapsulated superparamagnetic iron oxide particles as markers in an MRI-guided search for tumor-specific drug carriers
5. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes
6. Technetium-99m labelled liposomes to image experimental arthritis
7. Technetium-99m-labeled liposomes to image experimental colitis in rabbits: Comparison with technetium-99m-HMPAO-granulocytes and technetium-99m-HYNIC-IgG
8. Scintigraphic imaging of bacterial and fungal infection in granulocytopenic rats
9. Imaging experimental intraabdominal abscesses with 99mTc-PEG liposomes and 99mTc-HYNIC IgG
10. Scintigraphic evaluation of experimental chronic osteomyelitis
11. 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: Clinical evaluation
12. Liposomes for scintigraphic detection of infection and inflammation
13. Improved imaging of infections by avidin-induced clearance of 99mTc-biotin-PEG liposomes
14. ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging
15. Controlled delivery of Gd-containing liposomes to lymph nodes: Surface modification may enhance MRI contrast properties
16. Pharmacokinetics of stealth versus conventional liposomes: Effect of dose
17. Sterically stabilized liposomes
18. Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas
19. Initial clinical evaluation of pegylated-liposomal doxorubicin in solid tumors
20. Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma
21. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer
22. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma
23. Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma
24. Doxil (Caelyx): An exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
25. Phase II study of liposomal doxorubicin in advanced gynecologic cancers
26. Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum
27. Prolonged circulation time in vivo of large unilamelar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol)
28. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
29. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy
30. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer
31. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
32. Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies
33. Anaphylactic reactions to liposomal amphotericin
34. Chest discomfort associated with liposomal amphotericin B: Report of three cases and review of the literature
35. Allergic reactions and other rare side effects of liposomal amphotericin
36. Amphotericin B - Not so terrible
37. Anaphylactic reaction to liposomal amphotericin (AmBisome)
38. Tc-99m-PEG liposomes for the evaluation of colitis in Crohn's disease
39. Lessons for medicine and nuclear medicine research
40. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
41. Hemodynamic changes induced by liposomes and liposome -encapsulated hemoglobin in pigs: A model for pseudoallergic cardiopulmonary reactions to liposomes Role of complement and inhibition by soluble CR1 and anti-C5a antibody
42. The interaction of liposomes with the complement system
43. The complement system in liposome clearance: Can complement deposition be inhibited?
44. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes
45. Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids
46. Liposome-induced pulmonary hypertension: Properties and mechanism of a complement-mediated pseudoallergic reaction
47. Sterically stabilized liposomes: A hypothesis on the molecular origin of the extended circulation times
48. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice
49. Intrahepatic distribution of long-circulating liposomes containing poly(ethylene glycol) distearoyl phosphatidylethanolamine
50. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection IV Fate of liposomes in regional lymph nodes
51. Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue
52. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: Biodistribution and imaging studies
53. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy
54. Effect of lipid dose on the biodistribution and blood pool clearance kinetics of PEG modified technetium labeled lipid vesicles
55. Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose
56. Factors affecting the accelerated blood clearance of PEG liposomes upon repeated injection
57. Influence of dose on liposome clearance: Critical role of blood proteins
58. Liposome clearance from blood: Different animal species have different mechanisms
59. Repeat injection studies of technetium-99m-labeled PEG liposomes in the same animal
60. Effect of repeated intravenous administration on the circulation kinetics of poly(ethyleneglycol)-liposomes in rats
61. The role of immunoproteins in the survival of liposomes in the circulation
62. Natural antibodies against phospholipids and liposomes in humans
63. Anaphylactoid reactions mediated by autoantibodies to cholesterol in miniature pigs
64. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes
65. Co-existence of serum-dependent and serum-independent mechanisms for liposome clearance and involvement of non-Kupffer cells in liposome uptake by mouse liver
66. Recognition and clearance of liposomes containing phosphatidylserine are mediated by serum opsonin
67. A single dose of intravenously injected poloxamine-coated long-circulating particles triggers macrophage clearance of subsequent doses in rats
68. Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity implications in experimental and clinical oncology
69. An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin
70. Kinetics of Kupffer cells as shown by parabiosis and combined autoradiographic/immunohistochemical analysis